ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the following investor conferences in March
March 2, 2021
· 2 min read